CRC with the BRAF and KRAS mutations, derived from the serrated or conventional adenoma-to-carcinoma pathways (discussed further in detail later), are also represented by distinct epigenetic subtypes that may represent basic differences in transcriptional programs involved in these cancers. This evidence concerns the gene KRAS and carcinoma.